Molecular targets such as FGFR2 fusion, IDH1/2 mutation and HER2 amplification are proposed to be utilized for targeted therapies in CCA, but a majority of them are generally under clinical investigation (Table 1). Here, ERBB2 is linked to cholangiocarcinoma.